{"transactions":[{"id":4639635,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-13T21:12:13.000Z","date":"2026-10-12","kind":"grant","planned":false,"acquired":true,"shares":2465,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately."}],"balance_after":61571,"source":{"system":"sec-edgar","filing":"0001193125-26-420639","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1914847/000119312526420639/ownership.xml","form_type":"4"}},{"id":711251,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-10T23:41:32.000Z","date":"2026-07-10","kind":"grant","planned":false,"acquired":true,"shares":2852,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately."}],"balance_after":59106,"source":{"system":"sec-edgar","filing":"0001193125-26-301167","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526301167/ownership.xml","form_type":"4"}},{"id":810564,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-11T00:58:10.000Z","date":"2026-04-10","kind":"grant","planned":false,"acquired":true,"shares":3775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy.  All shares vest immediately."}],"balance_after":56254,"source":{"system":"sec-edgar","filing":"0001193125-26-151632","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526151632/ownership.xml","form_type":"4"}},{"id":830954,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:11:36.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23742,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":5.91,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":23742},"source":{"system":"sec-edgar","filing":"0001193125-26-120226","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120226/ownership.xml","form_type":"4"}},{"id":830953,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:11:36.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":23742,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":23742,"derivative":{"exercise_price":3.91,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":23742},"source":{"system":"sec-edgar","filing":"0001193125-26-120226","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120226/ownership.xml","form_type":"4"}},{"id":830952,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:11:36.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20724,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":17.28,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":20724},"source":{"system":"sec-edgar","filing":"0001193125-26-120226","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120226/ownership.xml","form_type":"4"}},{"id":830951,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:11:36.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":20724,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":20724,"derivative":{"exercise_price":3.91,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":20724},"source":{"system":"sec-edgar","filing":"0001193125-26-120226","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120226/ownership.xml","form_type":"4"}},{"id":888253,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-23T21:21:28.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":20400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date."}],"balance_after":20400,"derivative":{"exercise_price":1.04,"expiration_date":"2036-02-19","underlying":"Common Stock","underlying_shares":20400},"source":{"system":"sec-edgar","filing":"0001193125-26-064059","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526064059/ownership.xml","form_type":"4"}},{"id":939307,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-14T22:07:14.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":11560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy.  All shares vest immediately."}],"balance_after":52479,"source":{"system":"sec-edgar","filing":"0001193125-26-013041","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526013041/ownership.xml","form_type":"4"}},{"id":1019388,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-14T20:01:04.000Z","date":"2025-10-10","kind":"grant","planned":false,"acquired":true,"shares":10367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy.  All shares vest immediately."}],"balance_after":40919,"source":{"system":"sec-edgar","filing":"0001193125-25-238983","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312525238983/ownership.xml","form_type":"4"}},{"id":1088659,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-11T22:23:23.000Z","date":"2025-07-10","kind":"grant","planned":false,"acquired":true,"shares":11875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy.  All shares vest immediately."}],"balance_after":30552,"source":{"system":"sec-edgar","filing":"0000950170-25-095408","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025095408/ownership.xml","form_type":"4"}},{"id":1135576,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Optin (Right to Buy)","published_at":"2025-05-23T20:51:41.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":19111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on March 31, 2026, subject to the Reporting Person providing continuous service through such date."}],"balance_after":19111,"derivative":{"exercise_price":1.19,"expiration_date":"2035-05-21","underlying":"Common Stock","underlying_shares":19111},"source":{"system":"sec-edgar","filing":"0000950170-25-077035","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025077035/ownership.xml","form_type":"4"}},{"id":1173390,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T21:03:16.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":9705,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately."}],"balance_after":18677,"source":{"system":"sec-edgar","filing":"0000950170-25-053367","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025053367/ownership.xml","form_type":"4"}},{"id":1323010,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-23T23:40:38.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":8972,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy.  All shares vest immediately."}],"balance_after":8972,"source":{"system":"sec-edgar","filing":"0000950170-24-139800","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024139800/ownership.xml","form_type":"4"}},{"id":1472249,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-21T22:16:07.000Z","date":"2024-06-19","kind":"grant","planned":false,"acquired":true,"shares":64503,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the one-year anniversary of June 19, 2024 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date."}],"balance_after":64503,"derivative":{"exercise_price":2,"expiration_date":"2034-06-18","underlying":"Common Stock","underlying_shares":64503},"source":{"system":"sec-edgar","filing":"0000950170-24-076404","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024076404/ownership.xml","form_type":"4"}},{"id":1676640,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-18T23:19:41.000Z","date":"2024-01-16","kind":"sale","planned":false,"acquired":false,"shares":15907,"price":19.65,"value":312572.55,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":377542,"source":{"system":"sec-edgar","filing":"0000950170-24-005515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024005515/ownership.xml","form_type":"4"}},{"id":1676639,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-18T23:19:41.000Z","date":"2024-01-16","kind":"sale","planned":false,"acquired":false,"shares":84093,"price":19.65,"value":1652427.45,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":1995958,"source":{"system":"sec-edgar","filing":"0000950170-24-005515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024005515/ownership.xml","form_type":"4"}},{"id":1739342,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-16T23:57:17.000Z","date":"2023-11-14","kind":"sale","planned":true,"acquired":false,"shares":288,"price":16.146,"value":4650.048,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.285, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":393449,"source":{"system":"sec-edgar","filing":"0000950170-23-064609","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023064609/ownership.xml","form_type":"4"}},{"id":1739341,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-16T23:57:17.000Z","date":"2023-11-14","kind":"sale","planned":true,"acquired":false,"shares":1522,"price":16.146,"value":24574.212,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund, L.P"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.285, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2080051,"source":{"system":"sec-edgar","filing":"0000950170-23-064609","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023064609/ownership.xml","form_type":"4"}},{"id":1767941,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-03T23:21:18.000Z","date":"2023-10-02","kind":"sale","planned":false,"acquired":false,"shares":902,"price":16.07,"value":14495.14,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.10, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":393737,"source":{"system":"sec-edgar","filing":"0000950170-23-051733","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023051733/ownership.xml","form_type":"4"}},{"id":1767940,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-03T23:21:18.000Z","date":"2023-10-02","kind":"sale","planned":false,"acquired":false,"shares":4770,"price":16.07,"value":76653.9,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.10, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2081573,"source":{"system":"sec-edgar","filing":"0000950170-23-051733","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023051733/ownership.xml","form_type":"4"}},{"id":1767939,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-03T23:21:18.000Z","date":"2023-09-29","kind":"sale","planned":false,"acquired":false,"shares":15764,"price":16.28,"value":256637.92,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.95, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":394639,"source":{"system":"sec-edgar","filing":"0000950170-23-051733","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023051733/ownership.xml","form_type":"4"}},{"id":1767938,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-03T23:21:18.000Z","date":"2023-09-29","kind":"sale","planned":false,"acquired":false,"shares":83337,"price":16.28,"value":1356726.36,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.95, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2086343,"source":{"system":"sec-edgar","filing":"0000950170-23-051733","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023051733/ownership.xml","form_type":"4"}},{"id":1771626,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-29T21:40:05.000Z","date":"2023-09-28","kind":"sale","planned":false,"acquired":false,"shares":1356,"price":16.11,"value":21845.16,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":410403,"source":{"system":"sec-edgar","filing":"0000950170-23-050851","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023050851/ownership.xml","form_type":"4"}},{"id":1771625,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-29T21:40:05.000Z","date":"2023-09-28","kind":"sale","planned":false,"acquired":false,"shares":7160,"price":16.11,"value":115347.6,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund, L.P.("},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2169680,"source":{"system":"sec-edgar","filing":"0000950170-23-050851","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023050851/ownership.xml","form_type":"4"}},{"id":1771624,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-29T21:40:05.000Z","date":"2023-09-27","kind":"sale","planned":false,"acquired":false,"shares":134,"price":16.07,"value":2153.38,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.14, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":411759,"source":{"system":"sec-edgar","filing":"0000950170-23-050851","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023050851/ownership.xml","form_type":"4"}},{"id":1771623,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-29T21:40:05.000Z","date":"2023-09-27","kind":"sale","planned":false,"acquired":false,"shares":707,"price":16.07,"value":11361.49,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.14, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2176840,"source":{"system":"sec-edgar","filing":"0000950170-23-050851","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023050851/ownership.xml","form_type":"4"}},{"id":1780291,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-15T21:40:36.000Z","date":"2023-09-13","kind":"sale","planned":false,"acquired":false,"shares":64,"price":16,"value":1024.0,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":411893,"source":{"system":"sec-edgar","filing":"0000950170-23-048436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023048436/ownership.xml","form_type":"4"}},{"id":1780290,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-15T21:40:36.000Z","date":"2023-09-13","kind":"sale","planned":false,"acquired":false,"shares":336,"price":16,"value":5376.0,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":". Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2177547,"source":{"system":"sec-edgar","filing":"0000950170-23-048436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023048436/ownership.xml","form_type":"4"}},{"id":1784869,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-08T20:57:59.000Z","date":"2023-09-07","kind":"sale","planned":false,"acquired":false,"shares":537,"price":16.05,"value":8618.85,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":411957,"source":{"system":"sec-edgar","filing":"0000950170-23-047311","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023047311/ownership.xml","form_type":"4"}},{"id":1784868,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-08T20:57:59.000Z","date":"2023-09-07","kind":"sale","planned":false,"acquired":false,"shares":2841,"price":16.05,"value":45598.05,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2177883,"source":{"system":"sec-edgar","filing":"0000950170-23-047311","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023047311/ownership.xml","form_type":"4"}},{"id":1784867,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-08T20:57:59.000Z","date":"2023-09-06","kind":"sale","planned":false,"acquired":false,"shares":598,"price":16.02,"value":9579.96,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":412494,"source":{"system":"sec-edgar","filing":"0000950170-23-047311","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023047311/ownership.xml","form_type":"4"}},{"id":1784866,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-08T20:57:59.000Z","date":"2023-09-06","kind":"sale","planned":false,"acquired":false,"shares":3164,"price":16.02,"value":50687.28,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2180724,"source":{"system":"sec-edgar","filing":"0000950170-23-047311","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023047311/ownership.xml","form_type":"4"}},{"id":1796543,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-25T20:30:49.000Z","date":"2023-08-23","kind":"sale","planned":false,"acquired":false,"shares":64,"price":16,"value":1024.0,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":413092,"source":{"system":"sec-edgar","filing":"0000950170-23-044593","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023044593/ownership.xml","form_type":"4"}},{"id":1796542,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-25T20:30:49.000Z","date":"2023-08-23","kind":"sale","planned":false,"acquired":false,"shares":336,"price":16,"value":5376.0,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2183888,"source":{"system":"sec-edgar","filing":"0000950170-23-044593","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017023044593/ownership.xml","form_type":"4"}},{"id":1860920,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option\n(right to buy)","published_at":"2023-06-10T01:04:28.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":23742,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date."}],"balance_after":23742,"derivative":{"exercise_price":5.91,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":23742},"source":{"system":"sec-edgar","filing":"0000899243-23-015326","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924323015326/doc4.xml","form_type":"4"}},{"id":2222214,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-24T21:10:22.000Z","date":"2022-06-06","kind":"other","acquired":true,"shares":26511,"price":15,"value":397665.0,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 6, 2022, Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\") transferred to Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\") 26,511 shares of the Issuer's common stock, with a value of $15.00 per share, which is the per share cost of the shares acquired by AGHT Fund."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 6, 2022, Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\") transferred to Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\") 26,511 shares of the Issuer's common stock, with a value of $15.00 per share, which is the per share cost of the shares acquired by AGHT Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by AGHT Fund DE. The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":413156,"source":{"system":"sec-edgar","filing":"0000899243-22-024054","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322024054/doc4.xml","form_type":"4"}},{"id":2222213,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-24T21:10:22.000Z","date":"2022-06-06","kind":"other","acquired":false,"shares":26511,"price":15,"value":397665.0,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 6, 2022, Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\") transferred to Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\") 26,511 shares of the Issuer's common stock, with a value of $15.00 per share, which is the per share cost of the shares acquired by AGHT Fund."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 6, 2022, Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\") transferred to Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\") 26,511 shares of the Issuer's common stock, with a value of $15.00 per share, which is the per share cost of the shares acquired by AGHT Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by AGHT Fund. The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2184224,"source":{"system":"sec-edgar","filing":"0000899243-22-024054","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322024054/doc4.xml","form_type":"4"}},{"id":2270600,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-17T01:19:06.000Z","date":"2022-05-12","kind":"grant","acquired":true,"shares":20724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest as follows: 1/36 of the shares shall vest on each monthly anniversary as measured from March 25, 2022."}],"balance_after":20724,"derivative":{"exercise_price":17.28,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":20724},"source":{"system":"sec-edgar","filing":"0000899243-22-018282","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322018282/doc4.xml","form_type":"4"}},{"id":2313110,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2022-04-01T00:15:15.000Z","date":"2022-03-29","kind":"exercise","acquired":false,"shares":74230,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":74230},"source":{"system":"sec-edgar","filing":"0000899243-22-012988","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012988/doc4.xml","form_type":"4"}},{"id":2313109,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2022-04-01T00:15:15.000Z","date":"2022-03-29","kind":"exercise","acquired":false,"shares":392433,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":392433},"source":{"system":"sec-edgar","filing":"0000899243-22-012988","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012988/doc4.xml","form_type":"4"}},{"id":2313108,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2022-04-01T00:15:15.000Z","date":"2022-03-29","kind":"exercise","acquired":false,"shares":312415,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":312415},"source":{"system":"sec-edgar","filing":"0000899243-22-012988","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012988/doc4.xml","form_type":"4"}},{"id":2313107,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2022-04-01T00:15:15.000Z","date":"2022-03-29","kind":"exercise","acquired":false,"shares":1651636,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1651636},"source":{"system":"sec-edgar","filing":"0000899243-22-012988","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012988/doc4.xml","form_type":"4"}},{"id":2313106,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-01T00:15:15.000Z","date":"2022-03-29","kind":"purchase","acquired":true,"shares":166666,"price":15,"value":2499990.0,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2210735,"source":{"system":"sec-edgar","filing":"0000899243-22-012988","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012988/doc4.xml","form_type":"4"}},{"id":2313105,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-01T00:15:15.000Z","date":"2022-03-29","kind":"exercise","acquired":true,"shares":74230,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":386645,"source":{"system":"sec-edgar","filing":"0000899243-22-012988","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012988/doc4.xml","form_type":"4"}},{"id":2313104,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-01T00:15:15.000Z","date":"2022-03-29","kind":"exercise","acquired":true,"shares":392433,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":2044069,"source":{"system":"sec-edgar","filing":"0000899243-22-012988","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012988/doc4.xml","form_type":"4"}},{"id":2313103,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-01T00:15:15.000Z","date":"2022-03-29","kind":"exercise","acquired":true,"shares":312415,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund DE, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. (\"AGHT Fund DE\"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":312415,"source":{"system":"sec-edgar","filing":"0000899243-22-012988","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012988/doc4.xml","form_type":"4"}},{"id":2313102,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31009,"kind":"person","name":"Aziz Kabeer","position":1,"cik":"0001914847","reported_name":"Aziz Kabeer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-04-01T00:15:15.000Z","date":"2022-03-29","kind":"exercise","acquired":true,"shares":1651636,"ownership":{"direct":false,"nature":"By Adjuvant Global Health Technology Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Adjuvant Global Health Technology Fund, L.P. (\"AGHT Fund\"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. (\"AC GP\") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. (\"AC MGMT\"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities."}],"balance_after":1651636,"source":{"system":"sec-edgar","filing":"0000899243-22-012988","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012988/doc4.xml","form_type":"4"}}]}